208 related articles for article (PubMed ID: 18772169)
1. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
Seo MD; Lee KW; Lim JH; Yi HG; Kim DY; Oh DY; Kim JH; Im SA; Kim TY; Lee JS; Bang YJ
Jpn J Clin Oncol; 2008 Sep; 38(9):589-95. PubMed ID: 18772169
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
[TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK
Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK
Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Kaya AO; Coskun U; Gumus M; Dane F; Ozkan M; Isıkdogan A; Alkis N; Buyukberber S; Yumuk F; Budakoglu B; Demirci U; Berk V; Bilici A; Inal A; Arpacı E; Benekli M;
J Chemother; 2012 Aug; 24(4):217-20. PubMed ID: 23040686
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ
Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
[TBL] [Abstract][Full Text] [Related]
8. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
Erdem GU; Bozkaya Y; Ozdemir NY; Demirci NS; Yazici O; Zengin N
Bosn J Basic Med Sci; 2018 May; 18(2):170-177. PubMed ID: 28941466
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].
Kwon HJ; Park MI; Park SJ; Moon W; Kim SE; Lee HW; Choi YJ; Kim JH
Korean J Gastroenterol; 2015 Jul; 66(1):10-6. PubMed ID: 26194124
[TBL] [Abstract][Full Text] [Related]
11. [Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer].
Li J; Xu JM; Li J; Zhang XD; Bai Y; Chu YP; Wang YH; Liu DQ; Jin ML; Shen L
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):225-7. PubMed ID: 18756942
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
[TBL] [Abstract][Full Text] [Related]
13. Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC).
Wein A; Siebler J; Wolff K; Ostermeier N; Busse D; Hagel A; Koch F; Merx K; Neurath MF; Hofheinz RD
Anticancer Res; 2017 Jul; 37(7):3771-3779. PubMed ID: 28668873
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Kim JW; Lee KW; Kim KP; Lee JH; Hong YS; Kim JE; Kim SY; Park SR; Nam BH; Cho SH; Chung IJ; Park YS; Oh HS; Lee MA; Kang HJ; Park YI; Song EK; Han HS; Lee KT; Shin DB; Kang JH; Zang DY; Kim JH; Kim TW
Oncologist; 2017 Mar; 22(3):293-303. PubMed ID: 28209749
[TBL] [Abstract][Full Text] [Related]
15. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
16. FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.
Moretto R; Raimondo L; De Stefano A; Cella CA; Matano E; De Placido S; Carlomagno C
Anticancer Drugs; 2013 Oct; 24(9):980-5. PubMed ID: 23928570
[TBL] [Abstract][Full Text] [Related]
17. Irinotecan plus weekly 5-fluorouracil and leucovorin as salvage treatment for patients with metastatic colorectal cancer: a phase II trial.
Souglakos J; Vardakis N; Androulakis N; Kakolyris S; Kourousis C; Mavroudis D; Pallis A; Agelaki S; Kalbakis K; Georgoulias V
Dig Dis; 2007; 25(1):100-5. PubMed ID: 17384515
[TBL] [Abstract][Full Text] [Related]
18. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Neuzillet C; Hentic O; Rousseau B; Rebours V; Bengrine-Lefèvre L; Bonnetain F; Lévy P; Raymond E; Ruszniewski P; Louvet C; Hammel P
World J Gastroenterol; 2012 Sep; 18(33):4533-41. PubMed ID: 22969226
[TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice.
Pistelli M; Scartozzi M; Bittoni A; Galizia E; Berardi R; Cascinu S
Tumori; 2011; 97(3):275-9. PubMed ID: 21789002
[TBL] [Abstract][Full Text] [Related]
20. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
